Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2089-2095

  Xue, Jianmin ^a   Kass, Daniel J ^a   Bon, Jessica ^a   Vuga, Louis ^a   Tan, Jiangning ^a   Csizmadia, Eva ^b   Otterbein, Leo ^b   Soejima, Makoto ^a   Levesque, Marc C ^a   Gibson, Kevin F ^a   Kaminski, Naftali ^a   Pilewski, Joseph M ^a   Donahoe, Michael ^a   Sciurba, Frank C ^a   Duncan, Steven R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CELL AGGREGATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED;

EID: 84883364721     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203476     Document Type: Article

References (50)

1. Fernández Pérez, E. R., C. E. Daniels, D. R. Schroeder, J. St. Sauver, T. E. Hartman, B. J. Bartholmai, E. S. Yi, and J. H. Ryu. 2010. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a populationbased study. Chest 137: 129-137.
2. Borchers, A. T., C. Chang, C. L. Keen, and M. E. Gershwin. 2011. Idiopathic pulmonary fibrosis: an epidemiological and pathological review. Clin. Rev. Allergy Immunol. 40: 117-134.
3. O'Connell, O. J., M. P. Kennedy, and M. T. Henry. 2011. Idiopathic pulmonary fibrosis: treatment update. Adv. Ther. 28: 986-999.
4. Campbell, D. A., L. W. Poulter, G. Janossy, and R. M. du Bois. 1985. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 40: 405-411.
5. Marchal-Sommé, J., Y. Uzunhan, S. Marchand-Adam, D. Valeyre, V. Soumelis, B. Crestani, and P. Soler. 2006. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J. Immunol. 176: 5735-5739.
6. Zuo, F., N. Kaminski, E. Eugui, J. Allard, Z. Yakhini, A. Ben-Dor, L. Lollini, D. Morris, Y. Kim, B. DeLustro, et al. 2002. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA 99: 6292-6297.
7. Dall'Aglio, P. P., A. Pesci, G. Bertorelli, E. Brianti, and S. Scarpa. 1988. Study of immune complexes in bronchoalveolar lavage fluids. Respiration 54(Suppl. 1): 36-41.
8. Dobashi, N., J. Fujita, M. Murota, Y. Ohtsuki, I. Yamadori, T. Yoshinouchi, R. Ueda, S. Bandoh, T. Kamei, M. Nishioka, et al. 2000. Elevation of anticytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 178: 171-179.
9. Feghali-Bostwick, C. A., C. G. Tsai, V. G. Valentine, S. Kantrow, M. W. Stoner, J. M. Pilewski, A. Gadgil, M. P. George, K. F. Gibson, A. M. Choi, et al. 2007. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J. Immunol. 179: 2592-2599.
10. Ogushi, F., K. Tani, T. Endo, H. Tada, T. Kawano, T. Asano, L. Huang, Y. Ohmoto, M. Muraguchi, H. Moriguchi, and S. Sone. 2001. Autoantibodies to IL-1 a in sera from rapidly progressive idiopathic pulmonary fibrosis. J. Med. Invest. 48: 181-189.
11. Kurosu, K., Y. Takiguchi, O. Okada, N. Yumoto, S. Sakao, Y. Tada, Y. Kasahara, N. Tanabe, K. Tatsumi, M. Weiden, et al. 2008. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J. Immunol. 181: 756-767.
12. Taillé, C., S. Grootenboer-Mignot, C. Boursier, L. Michel, M. P. Debray, J. Fagart, L. Barrientos, A. Mailleux, N. Cigna, F. Tubach, et al. 2011. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183: 759-766.
13. Kahloon, R. A., J. Xue, A. Bhargava, E. Csizmadia, L. Otterbein, D. J. Kass, J. Bon, M. Soejima, M. C. Levesque, K. O. Lindell, et al. 2013. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am. J. Respir. Crit. Care Med. 187: 768-775.
14. Grigolo, B., I. Mazzetti, R. M. Borzì, I. D. Hickson, M. Fabbri, L. Fasano, R. Meliconi, and A. Facchini. 1998. Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 114: 339-346.
15. Yang, Y., J. Fujita, S. Bandoh, Y. Ohtsuki, I. Yamadori, T. Yoshinouchi, and T. Ishida. 2002. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin. Exp. Immunol. 128: 169-174.
16. Wallace, W. A., and S. E. Howie. 2001. Upregulation of tenascin and TGFbeta production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen. J. Pathol. 195: 251-256.
17. Magro, C. M., W. J. Waldman, D. A. Knight, J. N. Allen, T. Nadasdy, G. E. Frambach, P. Ross, and C. B. Marsh. 2006. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum. Immunol. 67: 284-297.
18. + regulatory T cells in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179: 1121-1130.
19. Gilani, S. R., L. J. Vuga, K. O. Lindell, K. F. Gibson, J. Xue, N. Kaminski, V. G. Valentine, E. K. Lindsay, M. P. George, C. Steele, and S. R. Duncan. 2010. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 5: e8959.
20. Xue, J., B. R. Gochuico, A. S. Alawad, C. A. Feghali-Bostwick, I. Noth, S. D. Nathan, G. D. Rosen, I. O. Rosas, S. Dacic, I. Ocak, et al. 2011. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 6: e14715.
21. Parra, E. R., R. A. Kairalla, C. R. Ribeiro de Carvalho, E. Eher, and V. L. Capelozzi. 2007. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 74: 159-169.
22. Daniil, Z., P. Kitsanta, G. Kapotsis, M. Mathioudaki, A. Kollintza, M. Karatza, J. Milic-Emili, C. Roussos, and S. A. Papiris. 2005. CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis. Respir. Res. 6: 81.
23. Erickson, S. B., S. B. Kurtz, J. V. Donadio, Jr., K. E. Holley, C. B. Wilson, and A. A. Pineda. 1979. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin. Proc. 54: 714-720.
24. Sem, M., O. Molberg, M. B. Lund, and J. T. Gran. 2009. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 48: 968-971.
25. Martinu, T., D. N. Howell, and S. M. Palmer. 2010. Acute cellular rejection and humoral sensitization in lung transplant recipients. Semin. Respir. Crit. Care Med. 31: 179-188.
26. Borie, R., M. P. Debray, C. Laine, M. Aubier, and B. Crestani. 2009. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur. Respir. J. 33: 1503-1506.
27. Keir, G. J., T. M. Maher, D. M. Hansell, C. P. Denton, V. H. Ong, S. Singh, A. U. Wells, and E. A. Renzoni. 2012. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur. Respir. J. 40: 641-648.
28. Furie, R., M. Petri, O. Zamani, R. Cervera, D. J. Wallace, D. Tegzová, J. Sanchez-Guerrero, A. Schwarting, J. T. Merrill,W.W. Chatham, et al.; BLISS-76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63: 3918-3930.
29. Cancro, M. P., D. P. D'Cruz, and M. A. Khamashta. 2009. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest. 119: 1066-1073.
30. Feghali-Bostwick, C. A., A. S. Gadgil, L. E. Otterbein, J. M. Pilewski, M. W. Stoner, E. Csizmadia, Y. Zhang, F. C. Sciurba, and S. R. Duncan. 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177: 156-163.
31. Bon, J., C. R. Fuhrman, J. L. Weissfeld, S. R. Duncan, R. A. Branch, C. C. Chang, Y. Zhang, J. K. Leader, D. Gur, S. L. Greenspan, and F. C. Sciurba. 2011. Radiographic emphysema predicts low bone mineral density in a tobaccoexposed cohort. Am. J. Respir. Crit. Care Med. 183: 885-890.
32. Levesque, M. C., M. A. Moody, K. K. Hwang, D. J. Marshall, J. F. Whitesides, J. D. Amos, T. C. Gurley, S. Allgood, B. B. Haynes, N. A. Vandergrift, et al. 2009. Transmitted/Founder HIV-1 induces B cell polyclonal differentiation and apoptosis with massive gastrointestinal tract germinal center loss in the earliest stages of infection. PLoS Med. 6: e1000107.
33. Hogg, J. C., F. Chu, S. Utokaparch, R. Woods, W. M. Elliott, L. Buzatu, R. M. Cherniack, R. M. Rogers, F. C. Sciurba, H. O. Coxson, and P. D. Paré. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350: 2645-2653.
34. Browning, J. L. 2006. B cells move to center stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Immunol. 5: 564-575.
35. Jacobi, A. M., K. Reiter, M. Mackay, C. Aranow, F. Hiepe, A. Radbruch, A. Hansen, G. R. Burmester, B. Diamond, P. E. Lipsky, and T. Dörner. 2008. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58: 1762-1773.
36. Souto-Carneiro, M. M., V. Mahadevan, K. Takada, R. Fritsch-Stork, T. Nanki, M. Brown, T. A. Fleisher, M. Wilson, R. Goldbach-Mansky, and P. E. Lipsky. 2009. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res. Ther. 11: R84.
37. Anolik, J. H., J. Barnard, A. Cappione, A. E. Pugh-Bernard, R. E. Felgar, R. J. Looney, and I. Sanz. 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50: 3580-3590.
38. Bossen, C., and P. Schneider. 2006. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18: 263-275.
39. Dillon, S. R., B. Harder, K. B. Lewis, M. D. Moore, H. Liu, T. R. Bukowski, N. B. Hamacher, M. M. Lantry, M. Maurer, C. M. Krejsa, et al. 2010. Blymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res. Ther. 12: R48.
40. Mayadas, T. N., G. C. Tsokos, and N. Tsuboi. 2009. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 120: 2012-2024.
41. Fu, S. M., U. S. Deshmukh, and F. Gaskin. 2011. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J. Autoimmun. 37: 104-112.
42. Yokota, S.-I., S. Chiba, H. Furuyama, and N. Fujii. 2010. Cerebrospinal fluids containing anti-HSP70 autoantibodies from multiple sclerosis patients augment HSP70-induced proinflammatory cytokine production in monocytic cells. J. Neuroimmunol. 218: 129-133.
43. Lu, M. C., N. S. Lai, H. C. Yu, H. B. Huang, S. C. Hsieh, and C. L. Yu. 2010. Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum. 62: 1213-1223.
44. Jang, J. Y., J. G. Jeong, H. R. Jun, S. C. Lee, J. S. Kim, Y. S. Kim, and M. H. Kwon. 2009. A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell. Mol. Life Sci. 66: 1985-1997.
45. Richards, T. J., N. Kaminski, F. Baribaud, S. Flavin, C. Brodmerkel, D. Horowitz, K. Li, J. Choi, L. J. Vuga, K. O. Lindell, et al. 2012. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 185: 67-76.
46. Aloisi, F., and R. Pujol-Borrell. 2006. Lymphoid neogenesis in chronic inflammatory disease. Nat. Rev. Immunol. 6: 205-217.
47. Perros, F., P. Dorfmüller, D. Montani, H. Hammad, W. Waelput, B. Girerd, N. Raymond, O. Mercier, S. Mussot, S. Cohen-Kaminsky, et al. 2012. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 185: 311-321.
48. Monaco, C., E. Andreakos, S. Kiriakidis, M. Feldmann, and E. Paleolog. 2004. T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr. Drug Targets Inflamm. Allergy 3: 35-42.
49. Wynn, T. A. 2004. Fibrotic disease and the TH1/TH2 paradigm. Nat. Rev. Immunol. 4: 583-594.
50. Donahoe, M., N. Chien, J. S. Raval, K. F. Gibson, M. Saul, Y. Zhang, and S. R. Duncan. 2013. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. Presented at the Am Thorac Soc International Meeting, May 2013. Am. J. Resp. Crit. Care Med. 187: A5712. Available at: http://cms. psav.com/cPaper2013/ats2013/myitinerary. Accessed: June 4, 20133